First Trust NYSE Arca Biotechnology Index Fund

FBT

Valor de mercado US$ 2,87 bi

The First Trust NYSE Arca Biotechnology Index Fund has outperformed the VanEck Biotech ETF on a one-year basis and over the last five years. The VanEck Biotech ETF offers a lower expense ratio of 0.35% compared to 0.55% for the First Trust fund.

Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.

A smart beta exchange traded fund, the First Trust NYSE Arca Biotechnology ETF (FBT) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market.

Launched on June 19, 2006, the First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

State Street SPDR S&P Biotech ETF carries a lower expense ratio of 0.35% compared to First Trust NYSE Arca Biotechnology Index Fund. FBT maintains a highly concentrated portfolio of only 30 holdings, while XBI spans 155 companies.

The iShares U.S. Healthcare ETF provides broad sector exposure with 100 holdings, while the First Trust NYSE Arca Biotechnology Index Fund focuses on a concentrated basket of 30 biotech stocks. The First Trust fund has delivered higher recent returns but experiences greater price volatility.

State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to the 0.55% charged by First Trust NYSE Arca Biotechnology Index Fund. First Trust's fund focuses exclusively on 30 biotechnology companies, while the SPDR ETF holds 60 stocks across the broader healthcare sector.

Biotech investors picking between the First Trust NYSE Arca Biotechnology Index Fund (NYSEARCA:FBT) and the iShares Biotechnology ETF (NASDAQ:IBB) often treat them as interchangeable proxies for the same sector.

iShares Global Healthcare ETF provides broad exposure to 110 global stocks while First Trust NYSE Arca Biotechnology Index Fund concentrates on 30 biotech positions. iShares Global Healthcare ETF carries a lower expense ratio of 0.40% compared to 0.55% for First Trust NYSE Arca Biotechnology Index Fund.

The State Street Health Care Select Sector SPDR ETF is significantly more affordable and larger than the First Trust NYSE Arca Biotechnology Index Fund, with an expense ratio of 0.08% compared to 0.55%. The First Trust NYSE Arca Biotechnology Index Fund focuses exclusively on biotechnology while the State Street Health Care Select Sector SPDR ETF provides broad exposure across the entire S&P 500 healthcare sector.